Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Subscribe to JNMT RSS feeds
Research ArticleTeaching Case Studies

Imaging Biomarkers in Lung Cancer with 68Ga-DOTATATE, 18F-Fluoride, and 18F-FDG PET/CT Scans and the Theranostics Paradigm

Mehdi Djekidel, Ghulam Syed and Aladdin Kanbour
Journal of Nuclear Medicine Technology September 2021, 49 (3) 281-283; DOI: https://doi.org/10.2967/jnmt.120.258343
Mehdi Djekidel
1NCCCR, Division of Oncology, Hamad Medical Corporation, Doha, Qatar;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ghulam Syed
2Department of Radiology, Division of Nuclear Medicine, Hamad Medical Corporation, Doha, Qatar; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aladdin Kanbour
3Department of Radiology, Division of Nuclear Medicine, Sidra Medicine, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Lung cancer is the number 1 cause of cancer deaths in the United States. The prognosis is quite grim with the exception of stage 1. When faced with several failed therapeutic regimens and rapid progression of the disease, considering alternative therapies such as radiopharmaceutical therapies may be an option. We describe the case of a 36-y-old man with lung adenocarcinoma who had imaging molecular characterization of his disease with 18F-FDG, 68Ga-DOTATATE, and 18F-fluoride PET/CT scans that were able to shed some light on molecular characterization of his disease and serve as a guide to potential targeted or personalized radiopharmaceutical therapeutic options.

  • lung cancer
  • lung adenocarcinoma
  • 18F-FDG
  • 68Ga-DOTATATE
  • 18F-fluoride
  • theranostics

Lung cancer is the number 1 cause of cancer deaths in the United States. The overall 5-y survival is 12% (1). The adenocarcinoma subtype is the most common primary lung cancer. The prognosis is quite grim with the exception of stage 1 (1,2). Somatostatin receptor expression has been described in lung cancer in general and also specifically in lung adenocarcinomas (3–6). Today, β- and α-emitters are available for treatment clinically. The Food and Drug Administration and the European Medicines Agency have approved 177Lu-DOTATATE and 223Ra for the treatment of gastroenteropancreatic neuroendocrine tumors and metastatic castration-resistant prostate cancers, respectively. However, these agents have also been used off-label, such as in neuroblastoma, pheochromocytoma, paraganglioma, and thyroid cancer patients. When faced with several failed therapeutic regimens and rapid progression of the disease, exploring alternative therapies such as radiopharmaceutical therapies may be an option. In a theranostic approach, the choice of the radiopharmaceutical used for treatment is important and will depend on the distribution of the disease and on uptake of the specific companion diagnostic agent.

CASE REPORT

We present the case of a 36-y-old man who quickly progressed to advanced, stage IV, moderately differentiated lung adenocarcinoma with metastasis to the liver and bone. Initial staging CT scans on May 12, 2019, showed an irregular right-upper-lobe mass and a few small subcentimeter mediastinal lymph nodes. Biopsy revealed a moderately differentiated lung adenocarcinoma that was anaplastic large cell lymphoma–negative, had PD-L1 expression in 35% of the tumor, and had a next-generation sequencing EGFR mutation in exon 20 and a JAK mutation in exon 14. The initial staging 18F-FDG scan showed uptake in the primary right-upper-lobe lesion and mediastinal lymph nodes, with no distant metastases (Fig. 1). Brain MRI findings were unremarkable. Right upper lobectomy and mediastinal lymph node dissection were performed, revealing invasive adenocarcinoma, mainly of the acinar subtype, and micropapillary components; there was a grade 1, well-differentiated single tumor measuring 4.2 × 2.8 × 2.5 cm (R0). Spread of the tumor through air spaces was present. Visceral pleural invasion was also present, as well as extensive lymphovascular invasion. Twelve of 16 regional lymph nodes were involved, with extranodal extension. The patient at initial surgery had stage IIIA disease (T2b N2 M0). Surgery was followed by 4 cycles of adjuvant cisplatin/vinorelbine tartrate and adjuvant radiotherapy. About 1 mo after completion of adjuvant chemoradiation, the patient presented with generalized bone pain, and an 18F-fluoride PET scan showed widespread bony metastasis (Fig. 2). This rapid progression of disease required an inpatient hospital stay and several narcotics for pain control. These findings prompted consideration of palliation with radionuclide-based treatments and bone-seeking agents such as 153Sm, 89Sr, 186Re, 188Re, or even 223Ra. However, bearing in mind that the patient might also have additional soft-tissue disease, a 68Ga-DOTATATE scan was performed to assess whether the disease was predominantly in the bones or also in the soft tissues (Fig. 3). This scan showed mostly bony lesions, slightly less prominent than on the 18F-fluoride scan, and minimal uptake in the pleura, best appreciated retrospectively. Restaging 18F-FDG PET done within a few days showed not only bony disease but also right-sided pleural disease and fewer than 5 subcentimeter liver deposits, also not appreciated on the 68Ga-DOTATATE scan (Fig. 4). The progression of disease and molecular characterization are summarized in Figure 5.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

18F-FDG PET/CT scan. Initial staging showing intensely 18F-FDG–avid right-upper-lobe mass with additional 18F-FDG–avid mediastinal lymph nodes. From right to left maximum-intensity-projection PET, coronal PET, coronal PET/CT, and axial PET/CT images.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

18F-fluoride PET/CT scan. Diffuse bony metastasis with intense 18F-fluoride uptake is seen. From right to left maximum-intensity-projection PET, coronal PET, sagittal PET/CT, and coronal PET/CT images.

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

68Ga-DOTATATE PET/CT scan. Diffuse bony metastasis is noted; uptake of 68Ga-DOTATATE is less prominent than that of 18F-fluoride in Figure 2. Liver and pleural involvement seen on subsequent 18F-FDG scan 1 wk later is not clearly appreciated with 68Ga-DOTATATE. From right to left maximum-intensity-projection PET, coronal PET, sagittal PET/CT, and coronal PET/CT images.

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

18F-FDG PET scan showing diffuse bony lesions but also detecting pleural and very minimal subtle liver disease not visualized on 68Ga-DOTATATE scan. From right to left maximum-intensity-projection PET, coronal PET, coronal PET/CT, and sagittal PET/CT images.

FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

(A) Initial staging 18F-FDG PET/CT scan. (B) Seven months later, 18F-fluoride PET/CT scan shows diffuse bony metastasis. (C) Additional 68Ga-DOTATATE PET/CT scan 2 wk later shows bony lesions less prominently than on 18F-fluoride scan, somewhat similar to follow-up 18F-FDG PET/CT scan. (D) Follow-up 18F-FDG PET/CT scan 1 wk later shows bony lesions and pleural and liver disease.

DISCUSSION

223Ra, an α-emitter selectively targeting bone metastasis, improved overall survival in the ALSYMPCA trial in castration-resistant metastatic prostate cancer (7,8). 177Lu-DOTATATE, a β-emitter, also improved overall survival, progression-free survival, and quality of life in patients with midgut neuroendocrine tumors from the NETTER-1 study (9). Although radiopharmaceutical therapies are seldom used in lung cancer, there is a growing interest in use in a variety of cancers. 177Lu-DOTATATE–based radiopharmaceutical therapies were also shown to improve overall and progression-free survival in bronchopulmonary carcinoids (10–13). Reports have also discussed the 177Lu-DOTATATE treatment paradigm in small cell lung cancer (14–17). Additionally, some reports and clinical trials are evaluating the benefit of 223Ra in non–small cell lung cancer (18–20). One of the prerequisites for 177Lu treatment is somatostatin receptor expression demonstrated on a companion diagnostic 177Lu-DOTATATE PET scan such as in our case. Positive bone scan results are the companion diagnostic for 223Ra. 18F-fluoride and 177Lu-DOTATATE PET scans offer a road map to assess the eligibility of a patient for a therapeutic option. This, of course, is currently limited to situations in which all conventional treatments have been exhausted. In our patient, we considered palliative treatment with radiopharmaceutical therapies with bone-seeking agents such as 153Sm, 89Sr, or even 223Ra. 177Lu-DOTATATE treatment was considered within a theranostic approach in the context of the patient’s also having some soft-tissue disease in the pleura and liver. Bone-seeking radiopharmaceuticals may be preferred in bone-predominant disease, and 177Lu-DOTATATE–based therapeutic radiopharmaceuticals may be preferred for non–bone-predominant disease. After declining any additional chemotherapy or immunotherapy and complete molecular characterization of the patient’s disease with PET, the patient then traveled to his home country and passed away shortly thereafter.

CONCLUSION

Considering that lung cancer patients frequently have a poor prognosis, radiopharmaceutical therapies should be kept in mind even if only for palliation of disease. In the era of theranostics, it becomes feasible to assess targets by pretherapy imaging such as, in our patient, with 18F-fluoride and 68Ga-DOTATATE. Further studies and clinical trials are needed for validation in lung cancer and other types of cancer.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online March 15, 2021.

REFERENCES

  1. 1.↵
    1. Myers DJ,
    2. Wallen JM.
    Lung adenocarcinoma. StatPerls website. https://www.statpearls.com/ArticleLibrary/viewarticle/24486. Updated June 26, 2021. Accessed August 2, 2021.
  2. 2.↵
    1. Li C,
    2. Lu H.
    Adenosquamous carcinoma of the lung. Onco Targets Ther. 2018;11:4829–4835.
    OpenUrl
  3. 3.↵
    1. Stumpf C,
    2. Kaemmerer D,
    3. Neubauer E,
    4. et al
    . Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer. J Cancer Res Clin Oncol. 2018;144:1921–1932.
    OpenUrl
  4. 4.
    1. Petito LC,
    2. García-Albéniz X,
    3. Logan RW,
    4. et al
    . Estimates of overall survival in patients with cancer receiving different treatment regimens: emulating hypothetical target trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. JAMA Netw Open. 2020;3:e200452.
    OpenUrl
  5. 5.
    1. Bombardieri E,
    2. Grippa F,
    3. Cataldo I,
    4. et al
    . Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy. Eur J Cancer. 1995;31A:184–188.
    OpenUrl
  6. 6.↵
    1. Traub T,
    2. Petkov V,
    3. Ofluoglu S,
    4. et al
    . 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med. 2001;42:1309–1315.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Parker C,
    2. Nilsson S,
    3. Heinrich D,
    4. et al
    . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Taneja SS.
    Re: alpha emitter radium-223 and survival in metastatic prostate cancer [editorial]. J Urol. 2014;191:657.
    OpenUrl
  9. 9.↵
    1. Strosberg JR,
    2. Wolin EM,
    3. Chasen BA,
    4. et al
    . First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors [abstract]. J Clin Oncol. 2018;36(suppl):4099.
    OpenUrl
  10. 10.↵
    1. Escala Cornejo RA,
    2. García-Talavera P,
    3. Navarro Martin M,
    4. et al
    . Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate. Ann Nucl Med. 2018;32:568–572.
    OpenUrl
  11. 11.
    1. Filosso PL,
    2. Ruffini E,
    3. Oliaro A,
    4. et al
    . Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide. J Thorac Cardiovasc Surg. 2005;129:819–824.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Mariniello A,
    2. Bodei L,
    3. Tinelli C,
    4. et al
    . Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016;43:441–452.
    OpenUrl
  13. 13.↵
    1. Naraev BG,
    2. Ramirez RA,
    3. Kendi AT,
    4. et al
    . Peptide receptor radionuclide therapy for patients with advanced lung carcinoids. Clin Lung Cancer. 2019;20:e376–e392.
    OpenUrl
  14. 14.↵
    1. Lewin J,
    2. Cullinane C,
    3. Akhurst T,
    4. et al
    . Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside. Eur J Nucl Med Mol Imaging. 2015;42:25–32.
    OpenUrl
  15. 15.
    1. Schmitt A,
    2. Bernhardt P,
    3. Nilsson O,
    4. et al
    . Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm. 2003;18:593–599.
    OpenUrlCrossRefPubMed
  16. 16.
    1. Schmitt A,
    2. Bernhardt P,
    3. Nilsson O,
    4. et al
    . Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer Biother Radiopharm. 2005;20:231–236.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Lapa C,
    2. Hänscheid H,
    3. Wild V,
    4. et al
    . Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. Oncotarget. 2016;7:20033–20040.
    OpenUrlPubMed
  18. 18.↵
    1. Taber AM,
    2. Riley D,
    3. Olszewski AJ,
    4. et al
    . Radium-223 following front-line chemotherapy for patients with non-small cell lung cancer and bone metastases [abstract]. J Clin Oncol. 2018;36(suppl):e21211.
    OpenUrl
  19. 19.
    1. Geva R,
    2. Lopez J,
    3. Danson S,
    4. et al
    . Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. Eur J Nucl Med Mol Imaging. 2019;46:1092–1101.
    OpenUrl
  20. 20.↵
    1. Reck M,
    2. Mileham KF,
    3. Clump DA,
    4. et al
    . 1420TiP A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC) [abstract]. Ann Oncol. 2020;31(suppl 4):S897–S898.
    OpenUrl
  • Received for publication October 11, 2020.
  • Accepted for publication January 27, 2021.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 49 (3)
Journal of Nuclear Medicine Technology
Vol. 49, Issue 3
September 1, 2021
  • Table of Contents
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Imaging Biomarkers in Lung Cancer with 68Ga-DOTATATE, 18F-Fluoride, and 18F-FDG PET/CT Scans and the Theranostics Paradigm
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Imaging Biomarkers in Lung Cancer with 68Ga-DOTATATE, 18F-Fluoride, and 18F-FDG PET/CT Scans and the Theranostics Paradigm
Mehdi Djekidel, Ghulam Syed, Aladdin Kanbour
Journal of Nuclear Medicine Technology Sep 2021, 49 (3) 281-283; DOI: 10.2967/jnmt.120.258343

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Imaging Biomarkers in Lung Cancer with 68Ga-DOTATATE, 18F-Fluoride, and 18F-FDG PET/CT Scans and the Theranostics Paradigm
Mehdi Djekidel, Ghulam Syed, Aladdin Kanbour
Journal of Nuclear Medicine Technology Sep 2021, 49 (3) 281-283; DOI: 10.2967/jnmt.120.258343
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • CASE REPORT
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Confirmation of Intracranial Neuroendocrine Metastasis Using 68Ga-DOTATATE PET/CT
  • 99mTc Pertechnetate in Diagnosis of Meckel’s Diverticulum in an Adult Patient: Case report
  • RARE CASE OF PHYLLODES TUMOUR OF BREAST WITH CARDIAC AND PANCREATIC METASTASES. FINDINGS ON FDG PET-CT.
Show more Teaching Case Studies

Similar Articles

Keywords

  • lung cancer
  • lung adenocarcinoma
  • 18F-FDG
  • 68Ga-DOTATATE
  • 18F-fluoride
  • theranostics
SNMMI

© 2023 Journal of Nuclear Medicine Technology

Powered by HighWire